Common use of Prosecution and Maintenance of GSK Patents Clause in Contracts

Prosecution and Maintenance of GSK Patents. GSK shall have the ------------------------------------------ exclusive right and obligation to (subject to GSK's election not to file, prosecute or maintain pursuant to Section 15.1.5) or to cause its licensors to, prepare, file and prosecute in a diligent manner (including without limitation by conducting interferences, oppositions and reexaminations or other similar proceedings), maintain (by timely paying all maintenance fees, renewal fees, and other such fees and costs required under applicable Laws) and extend all GSK Patents and related applications. GSK shall consult with Adolor prior to abandoning any GSK Patents or related applications that are material to the matters contemplated in this Agreement. GSK shall regularly advise Adolor of the status of all pending applications, including with respect to any hearings or other proceedings before any Governmental Authority, and, at Adolor's request, shall provide Adolor with copies of documentation relating to such applications, including all correspondence to and from any Governmental Authority. GSK shall solicit Adolor's advice and review of the nature and text of such patent applications and important prosecution matters related thereto in reasonably sufficient time prior to filing thereof, and GSK shall take into account Adolor's reasonable comments related thereto.

Prosecution and Maintenance of GSK Patents. GSK shall have the ------------------------------------------ exclusive right and obligation to (subject to GSK's election not to file, prosecute or maintain pursuant to Section 15.1.513.1.5) or to cause its licensors to, prepare, file and prosecute in a diligent manner (including without limitation by conducting interferences, oppositions and reexaminations or other similar proceedings), maintain (by timely paying all maintenance fees, renewal fees, and other such fees and costs required under applicable Laws) and extend all GSK Patents and related applications. Consistent with Section 13.6, GSK will consult with Theravance within the priority period for any patent application that is material to this Agreement concerning Countries in which corresponding applications will be filed provided always that GSK shall not be required to consult with Theravance under this Section 13.1.3 in relation to patent applications that GSK reasonably considers significant to activities beyond the scope of this Agreement, such as devices, delivery technology and/or any other proprietary GSK technology(ies). In the event the Parties cannot agree, GSK shall make the final decision. GSK shall consult with Adolor Theravance prior to abandoning any GSK Patents or related applications that are material to the matters contemplated in this Agreement. GSK shall regularly advise Adolor Theravance of the status of all pending applications, including with respect to any hearings or other proceedings before any Governmental Authority, and, at AdolorTheravance's request, shall provide Adolor Theravance with copies of documentation relating to such applications, including all correspondence to and from any Governmental Authority. Subject to Section 13.6, GSK shall solicit AdolorTheravance's advice and review of the nature and text of such patent applications and important prosecution matters related thereto in reasonably sufficient time prior to filing thereof, and GSK shall take into account AdolorTheravance's reasonable comments related relating thereto; provided that GSK shall have the final decision authority with respect to any action relating to a GSK Patent.

Prosecution and Maintenance of GSK Patents. GSK shall have the ------------------------------------------ exclusive right and obligation to (subject to GSK's ’s election not to file, prosecute or maintain pursuant to Section 15.1.513.1.5) or to cause its licensors to, prepare, file and prosecute in a diligent manner (including without limitation by conducting interferences, oppositions and reexaminations or other similar proceedings), maintain (by timely paying all maintenance fees, renewal fees, and other such fees and costs required under applicable Laws) and extend all GSK Patents and related applications. Consistent with Section 13.6, GSK will consult with Theravance within the priority period for any patent application that is material to this Agreement concerning Countries in which corresponding applications will be filed provided always that GSK shall not be required to consult with Theravance under this Section 13.1.3 in relation to patent applications that GSK reasonably considers significant to activities beyond the scope of this Agreement, such as devices, delivery technology and/or any other proprietary GSK technology(ies). In the event the Parties cannot agree, GSK shall make the final decision. GSK shall consult with Adolor Theravance prior to abandoning any GSK Patents or related applications that are material to the matters contemplated in this Agreement. GSK shall regularly advise Adolor Theravance of the status of all pending applications, including with respect to any hearings or other proceedings before any Governmental Authority, and, at Adolor's Theravance’s request, shall provide Adolor Theravance with copies of documentation relating to such applications, including all correspondence to and from any Governmental Authority. Subject to Section 13.6, GSK shall solicit Adolor's Theravance’s advice and review of the nature and text of such patent applications and important prosecution matters related thereto in reasonably sufficient time prior to filing thereof, and GSK shall take into account Adolor's Theravance’s reasonable comments related relating thereto; provided that GSK shall have the final decision authority with respect to any action relating to a GSK Patent.

Prosecution and Maintenance of GSK Patents. GSK shall have the ------------------------------------------ exclusive right and obligation to (subject to GSK's election not to file, prosecute or maintain pursuant to Section 15.1.513.1.5) or to cause its licensors to, prepare, file and prosecute in a diligent manner (including without limitation by conducting interferences, oppositions and reexaminations or other similar proceedings), maintain (by timely paying all maintenance fees, renewal fees, and other such fees and costs required under applicable Laws) and extend all GSK Patents and related applications. Consistent with Section 2.3.3, GSK will consult with Theravance within the priority period for any patent application that is material to this Agreement concerning Countries in which corresponding applications will be filed. In the event the Parties can not agree, GSK shall make the final decision. GSK shall consult with Adolor Theravance prior to abandoning any GSK Patents or related applications that are material to the matters contemplated in this Agreement. GSK shall regularly advise Adolor Theravance of the status of all pending applications, including with respect to any hearings or other proceedings before any Governmental Authority, and, at AdolorTheravance's request, shall provide Adolor Theravance with copies of documentation relating to such applications, including all correspondence to and from any Governmental Authority. Subject to Section 2.3.3, GSK shall solicit AdolorTheravance's advice and review of the nature and text of such patent applications and important prosecution matters related thereto in reasonably sufficient time prior to filing thereof, and GSK shall take into account AdolorTheravance's reasonable comments related relating thereto; provided that GSK shall have the final decision authority with respect to any action relating to a GSK Patent.

Prosecution and Maintenance of GSK Patents. GSK shall have the ------------------------------------------ exclusive right and obligation to (subject to GSK's ’s election not to file, prosecute or maintain pursuant to Section 15.1.513.1.5) or to cause its licensors to, prepare, file and prosecute in a diligent manner (including without limitation by conducting interferences, oppositions and reexaminations or other similar proceedings), maintain (by timely paying all maintenance fees, renewal fees, and other such fees and costs required under applicable Laws) and extend all GSK Patents and related applications. Consistent with Section 2.3.3, GSK will consult with Theravance within the priority period for any patent application that is material to this Agreement concerning Countries in which corresponding applications will be filed. In the event the Parties can not agree, GSK shall make the final decision. GSK shall consult with Adolor Theravance prior to abandoning any GSK Patents or related applications that are material to the matters contemplated in this Agreement. GSK shall regularly advise Adolor Theravance of the status of all pending applications, including with respect to any hearings or other proceedings before any Governmental Authority, and, at Adolor's Theravance’s request, shall provide Adolor Theravance with copies of documentation relating to such applications, including all correspondence to and from any Governmental Authority. Subject to Section 2.3.3, GSK shall solicit Adolor's Theravance’s advice and review of the nature and text of such patent applications and important prosecution matters related thereto in reasonably sufficient time prior to filing thereof, and GSK shall take into account Adolor's Theravance’s reasonable comments related relating thereto; provided that GSK shall have the final decision authority with respect to any action relating to a GSK Patent.